TMS for Alcoholism
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores a non-invasive brain treatment called transcranial magnetic stimulation (TMS) to determine its effectiveness in reducing alcohol cravings. TMS uses magnetic pulses to stimulate specific brain areas linked to drinking behavior. The study will test TMS, specifically MPFC Theta Burst Stimulation, on individuals who drink heavily and have an alcohol use disorder, examining its impact on their reaction to alcohol-related images. Participants should consume more than 14 drinks a week for women or 21 for men and experience frequent heavy drinking days. As an unphased trial, this study offers participants the opportunity to contribute to groundbreaking research on innovative treatments for alcohol use disorder.
Will I have to stop taking my current medications?
The trial requires that participants do not take certain medications known to improve alcohol treatment outcomes, like naltrexone, acamprosate, or topiramate, and psychiatric/sleeping medications, except for stable antidepressants/SSRIs. If you are on these medications, you may need to stop them to participate.
What prior data suggests that TMS and TBS are safe for use in humans?
Research has shown that theta burst stimulation (TBS) applied to the medial prefrontal cortex (MPFC) is generally well-tolerated. In one study, participants received this treatment for ten days and found it manageable, experiencing no major negative side effects. The study also found that TBS reduced alcohol consumption and lessened the brain's response to alcohol-related cues for up to three months. This suggests the treatment offers potential benefits and is safe for short-term use.
Overall, current evidence supports using this non-invasive brain stimulation for treating alcohol use disorder, indicating it is a safe option for those considering joining a clinical trial.12345Why are researchers excited about this trial?
Researchers are excited about using MPFC Theta Burst Stimulation (TBS) for alcoholism because it employs a cutting-edge technique called continuous theta burst stimulation directly to the brain's medial prefrontal cortex (mPFC). Unlike standard treatments like medications or behavioral therapy, TBS offers a non-invasive approach that targets specific brain areas involved in addiction. This method uses rapid, repetitive magnetic pulses to potentially alter brain activity linked to alcohol cravings, providing a novel way to address the underlying neurological aspects of alcoholism. The precision and non-invasive nature of TBS make it a promising new avenue for those seeking alternatives to traditional therapies.
What evidence suggests that MPFC Theta Burst Stimulation is effective for reducing alcohol cravings?
Research shows that MPFC Theta Burst Stimulation (TBS) may help reduce alcohol consumption. In this trial, participants will receive either real TBS or sham TBS to the medial prefrontal cortex. Earlier studies found that ten days of TBS treatment on the medial prefrontal cortex (a part of the brain linked to drinking habits) led to less drinking and a reduced brain response to alcohol-related cues. These effects lasted for up to three months after starting treatment. This suggests that TBS might help decrease the desire for alcohol by changing how the brain reacts to alcohol-related images. Early findings also indicate that TBS is generally well tolerated, meaning participants usually don't experience significant negative effects.12367
Are You a Good Fit for This Trial?
This trial is for adults aged 21-65 who drink heavily, meeting specific criteria (over 14 drinks per week for women and over 21 for men). Participants must have Alcohol Use Disorder as defined by DSM-V. Exclusions include unstable medical conditions, metal implants above the neck, pregnancy or inadequate birth control use, certain psychiatric disorders, history of severe head injury or substance abuse other than nicotine.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive theta burst stimulation (TBS) to the medial prefrontal cortex (mPFC) over 4 weeks, with 36 sessions (3x/day on each of 3 days/week)
Follow-up
Participants are monitored for changes in drinking behavior and brain reactivity to alcohol cues over a 3-month period
What Are the Treatments Tested in This Trial?
Interventions
- MPFC Theta Burst Stimulation
Find a Clinic Near You
Who Is Running the Clinical Trial?
Medical University of South Carolina
Lead Sponsor
National Institutes of Health (NIH)
Collaborator
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Collaborator